Recent developments include a terminated agreement to sell a majority stake in Pocono Pharmaceuticals, leadership changes with the CEO temporarily stepping aside and returning, and ongoing clinical and regulatory progress for AVERSA™ Fentanyl.

• In December 2025, NutriBand agreed to sell a 90% stake in its subsidiary Pocono Pharmaceuticals to EarthVision Bio for $5 million, but the transaction was terminated due to the purchaser’s failure to pay late fees and close the deal [N1].
• Co-founder Gareth Sheridan returned to the role of CEO in October 2025 after temporarily stepping aside to run in the Irish Presidential election [N7].
• NutriBand reported a Q2 2025 loss and lagging revenue performance [N8].
• The company completed a meeting with the FDA in September 2025 to obtain feedback on Chemistry, Manufacturing, and Controls plans for AVERSA™ Fentanyl, incorporating feedback into development [S1].

NutriBand’s proprietary AVERSA™ technology addresses a critical public health issue by aiming to reduce opioid patch abuse, which could differentiate its products in the market. The company’s partnership with an experienced CDMO, Kindeva Drug Delivery, supports its development and potential commercialization efforts. The pipeline expansion to other abuse-prone drugs like buprenorphine and methylphenidate broadens its market opportunity. NutriBand’s contract manufacturing and research subsidiaries provide current revenue streams to support operations. Successful regulatory progress and eventual product approvals could enhance the company’s commercial prospects and shareholder value.

NutriBand operates in a highly regulated and competitive pharmaceutical environment with significant risks including the uncertainty of obtaining FDA approval for its products. The company has incurred substantial losses and depends on raising additional capital to fund ongoing development. Its lead product and pipeline candidates are in early development stages, with no approved products generating significant revenue. The termination of the planned sale of its Pocono Pharmaceuticals subsidiary indicates challenges in executing strategic transactions. Market acceptance, manufacturing scale-up, intellectual property protection, and regulatory delays pose material risks to the company’s business and financial performance.

NutriBand’s moat is centered on its proprietary AVERSA™ abuse deterrent transdermal technology, which aims to uniquely deter abuse of opioid and stimulant transdermal patches by incorporating aversive agents that are not delivered to the skin but deter oral, buccal, and inhalation abuse routes. This technology targets a significant unmet need given the opioid abuse epidemic and the lack of abuse deterrent features in existing fentanyl patches. The company’s exclusive development partnership with Kindeva Drug Delivery for AVERSA™ Fentanyl and its patent portfolio provide barriers to entry. However, the early-stage nature of its products and the competitive pharmaceutical environment present ongoing challenges to establishing a sustainable competitive advantage.

• Regulatory Approval Risk: NutriBand’s products require FDA approval, which involves extensive preclinical and clinical testing. There is no assurance that the company will obtain necessary approvals or that the FDA will accept its regulatory pathways or data.
• Financial and Capital Risk: The company has incurred significant losses and negative cash flow. It depends on raising additional capital to fund product development and operations. Failure to secure funding could impair its ability to continue development or operations.
• Market and Competitive Risk: NutriBand faces competition from established pharmaceutical companies and emerging technologies. Its products must achieve market acceptance and reimbursement to be commercially successful.
• Operational and Manufacturing Risk: Manufacturing must comply with FDA cGMP regulations and is subject to inspections. Any manufacturing issues or delays could impact product development and commercialization.
• Leadership and Execution Risk: Changes in executive leadership and the ability to attract and retain key personnel affect the company’s strategic direction and operational execution.

• NutriBand Inc. is a Nevada corporation incorporated in January 2016 focused on developing a portfolio of transdermal pharmaceutical products.
• The company’s proprietary AVERSA™ abuse deterrent transdermal technology is designed to be incorporated into existing transdermal patches containing drugs susceptible to abuse such as opioids and stimulants.
• NutriBand operates through two subsidiaries: Pocono Pharmaceuticals (contract manufacturing for health, wellness, and OTC pharmaceutical customers) and 4P Therapeutics (contract research and development services for pharmaceutical and medical device customers).
• The company’s principal offices are in Orlando, Florida, with a manufacturing facility in Cherryville, North Carolina.
• NutriBand primarily operates and derives most of its revenues in the United States.
• The lead product under development is AVERSA™ Fentanyl, an abuse deterrent fentanyl transdermal system combining an approved generic fentanyl patch with AVERSA™ technology to reduce abuse and misuse.
• NutriBand has a commercial development and clinical supply agreement with Kindeva Drug Delivery, a global CDMO, formalized in February 2025 to develop AVERSA™ Fentanyl.
• The development program for AVERSA™ Fentanyl includes preclinical and clinical studies, including a Phase 1 human abuse potential study, aiming for FDA approval via a 505(b)(2) NDA pathway.
• Additional pipeline products include AVERSA™ Buprenorphine and AVERSA™ Methylphenidate, with development programs similar to AVERSA™ Fentanyl.
• NutriBand acquired 4P Therapeutics in 2018, shifting focus to pharmaceutical transdermal products development, including novel transdermal delivery of peptides and proteins as alternatives to injections.
• The company acquired Pocono Coated Products’ transdermal, topical, cosmetic, and nutraceutical business in 2020, forming Pocono Pharmaceuticals as a wholly owned subsidiary.
• NutriBand’s products require FDA approval before marketing in the U.S., involving extensive preclinical and clinical testing and regulatory review.
• The company’s manufacturing will comply with FDA current Good Manufacturing Practices (cGMP) and is subject to FDA inspections.
• NutriBand faces risks common to early-stage pharmaceutical companies, including undercapitalization, cash shortages, regulatory approval uncertainties, and competition.
• The company reported fiscal year 2026 (ending January 31, 2026) revenue of $2,036,651 and a net loss of $8,229,632, with basic and diluted EPS of -$2.58.
• As of January 31, 2026, NutriBand had cash and cash equivalents of $4,574,857, current assets of $4,988,718, current liabilities of $784,281, a current ratio of 6.36, and a cash ratio of 5.83.
• In 2025, CEO Gareth Sheridan temporarily stepped aside to run in the Irish Presidential election; co-founder and chairman Serguei Melnik served as acting CEO during this period and resumed strategic leadership after the election.
• In December 2025, NutriBand agreed to sell a 90% stake in its subsidiary Pocono Pharmaceuticals to EarthVision Bio for $5 million, but the transaction was later terminated due to purchaser’s failure to pay late fees and close the deal.
• NutriBand’s revenues are currently based on contract manufacturing and research services through its subsidiaries rather than product sales.
• The company’s AVERSA™ technology aims to deter abuse by incorporating aversive agents into transdermal patches, which are not delivered to the skin but released to deter oral, buccal, and inhalation abuse routes.
• NutriBand’s development pipeline includes products targeting chronic pain, opioid use disorder, and ADHD, with a focus on improving compliance and safety through transdermal delivery.
• NutriBand’s regulatory strategy includes leveraging the FDA’s 505(b)(2) pathway to reference existing safety and efficacy data for approved drugs, potentially reducing clinical trial requirements.
• The company’s business and financial results are subject to risks including economic uncertainty, regulatory delays, competition, intellectual property protection, and the ability to raise capital.
• NutriBand’s stock price has experienced volatility, and future equity offerings may dilute existing shareholders.